PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exploring Biomarkers of Phosphoinositide 3‐Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer

(2019) Virginia G. Kaklamani et al.   ONCOLOGIST

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma

(2019) Carolina Caro-Vegas et al.   mBio

A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer

(2019) Hye Joung Choi et al.   GYNECOLOGIC ONCOLOGY

The role of mTOR in ovarian cancer, polycystic ovary syndrome and ovarian aging

(2018) Jin Liu et al.   CLINICAL ANATOMY

INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway

(2018) Ying Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer

(2018) Mei Ding et al.   MOLECULAR CANCER RESEARCH

Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells

(2018) Alina Sesarman et al.   Pharmacological Reports

Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance

(2018) Augustin Le Naour et al.   Oncotarget

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

(2018) Brandon Bumbaca et al.   Acta Pharmaceutica Sinica B

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer

(2018) Diyou Li et al.   Analytical Cellular Pathology

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

(2018) Felix Mensah et al.   OncoTargets and Therapy

Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment

(2018) Alina Sesarman et al.   Drug Delivery and Translational Research

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

(2017) Maria Gasparri et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

PtdIns3P controls mTORC1 signaling through lysosomal positioning

(2017) Zhi Hong et al.   JOURNAL OF CELL BIOLOGY

Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop

(2017) Bhushan Thakur et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway

(2017) Chen-Zheng Huang et al.   ONCOLOGY REPORTS

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer

(2017) Andréia Cristina de Melo et al.   Oxidative Medicine and Cellular Longevity

Preclinical study of CC223 as a potential anti-ovarian cancer agent

(2017) Zhenzhen Jin et al.   Oncotarget

The Dualistic Model of Ovarian Carcinogenesis

(2016) Robert J. Kurman et al.   AMERICAN JOURNAL OF PATHOLOGY

c-Rel and its many roles in cancer: an old story with new twists

(2016) Jill E Hunter et al.   BRITISH JOURNAL OF CANCER

AKT in cancer: new molecular insights and advances in drug development

(2016) Prabhjot S. Mundi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling

(2016) Shu Tang et al.   CANCER LETTERS

Targeting Inflammation in Cancer Prevention and Therapy

(2016) J. Todoric et al.   Cancer Prevention Research

Yin and yang of 4E-BP1 in cancer

(2016) Ren Wang et al.   CELL CYCLE

4E-BP1, a multifactor regulated multifunctional protein

(2016) Xiaoyu Qin et al.   CELL CYCLE

The rise of genomic profiling in ovarian cancer

(2016) Rebecca A. Previs et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy

(2016) Christos E. Zois et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers

(2016) Kaiming Sun et al.   MOLECULAR CANCER THERAPEUTICS

NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer

(2016) A R Özeş et al.   ONCOGENE

Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis

(2016) J Musa et al.   ONCOGENE

Chemoresistance and targeted therapies in ovarian and endometrial cancers

(2016) Kevin Brasseur et al.   Oncotarget

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

(2016) Dong Wang et al.   Oncotarget

Akt isoform specific effects in ovarian cancer progression

(2016) Nicolle M. Linnerth-Petrik et al.   Oncotarget

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma

(2016) Maria-Carmela Speranza et al.   Scientific Reports

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

(2015) Seiji Mabuchi et al.   GYNECOLOGIC ONCOLOGY

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer

(2015) Zhi Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

mTOR: a pharmacologic target for autophagy regulation

(2015) Young Chul Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Phosphoinositide-specific phospholipase C in health and disease

(2015) Lucio Cocco et al.   JOURNAL OF LIPID RESEARCH

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment

(2015) Laura R. H. Ip et al.   Oncotarget

The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines

(2015) Huimin Bai et al.   Oncotarget

A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation

(2015) Guang Yang et al.   Cell Reports

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

(2015) Bianca Cheaib et al.   Chinese Journal of Cancer

PI3K/AKT signaling pathway and cancer: an updated review

(2014) Miriam Martini et al.   ANNALS OF MEDICINE

PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression

(2014) Huijuan Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of Rapamycin) by IκB Kinase α (IKKα)

(2014) Han C. Dan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Classes of phosphoinositide 3-kinases at a glance

(2014) S. Jean et al.   JOURNAL OF CELL SCIENCE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis

(2014) J. Cai et al.   ONCOLOGIST

NF-κB Inducing Kinase, a Central Signaling Component of the Non-Canonical Pathway of NF-κB, Contributes to Ovarian Cancer Progression

(2014) Masaya Uno et al.   PLoS One

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context

(2014) F. Schmit et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The structural basis for mTOR function

(2014) Domagoj Baretić et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Role of Integrin Alpha4 in Drug Resistance of Leukemia

(2014) Stephanie Shishido et al.   Frontiers in Oncology

Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy

(2013) Hai-Xin Yuan et al.   Autophagy

Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway

(2013) Nasser Ghaly Yousif   CELL BIOLOGY INTERNATIONAL

The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells

(2013) Hui Cai et al.   Cell Communication and Signaling

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

(2013) B. Weigelt et al.   CLINICAL CANCER RESEARCH

Immune escape of AKT overexpressing ovarian cancer cells

(2013) JENS C. HAHNE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Curcumin Suppresses Doxorubicin-Induced Epithelial–Mesenchymal Transition via the Inhibition of TGF-β and PI3K/AKT Signaling Pathways in Triple-Negative Breast Cancer Cells

(2013) Wei-Chih Chen et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate

(2013) York Posor et al.   NATURE

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

NF-κB is a critical mediator of BRCA1-induced chemoresistance

(2013) M T Harte et al.   ONCOGENE

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Identification of ovarian cancer driver genes by using module network integration of multi-omics data

(2013) O. Gevaert et al.   Interface Focus

Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy

(2013) P. Godwin et al.   Frontiers in Oncology

Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review

(2012) J Borley et al.   BRITISH JOURNAL OF CANCER

Renin activates PI3K-Akt-eNOS signalling through the angiotensin AT1 and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii

(2012) Wen-Han Cheng et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

(2012) Balázs Győrffy et al.   ENDOCRINE-RELATED CANCER

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

(2012) Paul G Richardson et al.   Expert Opinion on Drug Metabolism & Toxicology

The noncanonical NF-κB pathway

(2012) Shao-Cong Sun   IMMUNOLOGICAL REVIEWS

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice

(2012) Kathryn M. Kinross et al.   JOURNAL OF CLINICAL INVESTIGATION

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

(2012) C. P. Carden et al.   MOLECULAR CANCER THERAPEUTICS

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The evolution of the TOR pathway and its role in cancer

(2012) E M Beauchamp et al.   ONCOGENE

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro

(2012) J.C. HAHNE et al.   ONCOLOGY REPORTS

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent

(2012) Jing Ni et al.   Cancer Discovery

Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor

(2011) Inma M. Berenjeno et al.   BIOCHEMICAL JOURNAL

FoxO transcription factors; Regulation by AKT and 14-3-3 proteins

(2011) Guri Tzivion et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The Akt kinases: Isoform specificity in metabolism and cancer

(2011) Eva Gonzalez et al.   CELL CYCLE

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway

(2011) Ilana Chefetz et al.   CELL CYCLE

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors

(2011) Francesco Dituri et al.   Clinical & Developmental Immunology

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

(2011) Jia Huang et al.   GENES CHROMOSOMES & CANCER

Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways

(2011) Min Huan Wu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

NF-κB is 25

(2011) David Baltimore   NATURE IMMUNOLOGY

Genomic Complexity and AKT Dependence in Serous Ovarian Cancer

(2011) Aphrothiti J. Hanrahan et al.   Cancer Discovery

Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis

(2010) Xiaofeng Zhao et al.   ADVANCED DRUG DELIVERY REVIEWS

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells

(2010) Dong-Jun Peng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Acetylation of p65 at lysine 314 is important for late NF-κB-dependent gene expression

(2010) Karin M Rothgiesser et al.   BMC GENOMICS

Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer

(2010) Christina M. Annunziata et al.   CANCER

Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival

(2010) Bryan C. Barnhart et al.   CANCER BIOLOGY & THERAPY

Activation of NF- B Signaling by Inhibitor of NF- B Kinase   Increases Aggressiveness of Ovarian Cancer

(2010) L. Hernandez et al.   CANCER RESEARCH

Structural studies of NF-κB signaling

(2010) Chao Zheng et al.   CELL RESEARCH

Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition

(2010) Calvin K. Yip et al.   MOLECULAR CELL

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS

Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma

(2010) Natini Jinawath et al.   PLoS One

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

(2010) C. G. Fedele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

(2010) J. J. Wallin et al.   Science Translational Medicine

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

(2009) Christina Gewinner et al.   CANCER CELL

Cleaved caspase-3 and nuclear factor-κB p65 are prognostic factors in metastatic serous ovarian carcinoma

(2009) Lilach Kleinberg et al.   HUMAN PATHOLOGY

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction?

(2008) M VADAS   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms

(2008) HuiJuan Wu et al.   CANCER LETTERS

Shared Principles in NF-κB Signaling

(2008) Matthew S. Hayden et al.   CELL

Targeting SphK1 as a New Strategy against Cancer

(2008) Dai Shida et al.   CURRENT DRUG TARGETS

Akt-dependent regulation of NF- B is controlled by mTOR and Raptor in association with IKK

(2008) H. C. Dan et al.   GENES & DEVELOPMENT

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

(2008) J. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

(2008) Shidong Jia et al.   NATURE

A Putative Mitotic Checkpoint Dependent on mTOR Function Controls Cell Proliferation and Survival in Ovarian Granulosa Cells

(2008) Aylin Yaba et al.   Reproductive Sciences

Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFκB pathway

(2007) Byeong Hyeok Choi et al.   CANCER LETTERS